Phenex raises €6M to achieve ROR success
This article was originally published in Scrip
Phenex Pharmaceuticals, the Ludwigshafen-based nuclear receptor-focused drug discovery company, has raised €6 million in a series C round to finance its early-stage RORgt (Retinoic Acid Related Orphan Receptor gamma t) programme and the clinical development of the compound in its farnesoid X receptor (FXR) programme. In addition to its existing investors, Phenex has attracted money from high net worth individuals associated with the Boehringer family, one of Europe’s foremost pharmaceutical industry dynasties.
You may also be interested in...
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.